848358-06-5

Usage

Molecular Weight

163.22 g/mol The molecular weight is the mass of one mole of the compound.

Structure

Thieno[3,2-c]pyrazole with a methanol group at the 5th position The structure refers to the arrangement of atoms in the compound.

Heterocyclic compound

Containing a thieno and pyrazole ring A heterocyclic compound is a compound that contains a ring of atoms with at least one ring member being a different element than carbon.

Substitution

Methanol group at the 5th position The substitution refers to the replacement of a hydrogen atom in the ring with a methanol group.

Pharmacological properties

Potential use in the treatment of various medical conditions The pharmacological properties refer to the potential therapeutic effects of the compound.

Hazards

Handle with care and follow safety guidelines The hazards refer to the potential risks associated with handling the compound.

Upstream product

• 36050-35-8 5-methyl-4-nitro-thiophene-2-carboxylic acid 
• 1246552-43-1 methyl 1H-thieno[3,2-c]pyrazole-5-carboxylate 
• 848357-31-3 methyl 1-acetyl-1H-thieno[3,2-c]pyrazole-5-carboxylate 
• 501082-56-0 4-amino-5-methylthiophene-2-carboxylic acid methyl ester 
• 56921-01-8 5-methyl-4-nitro-thiophene-2-carboxylic acid methyl ester 
• 1918-79-2 2-methylthiophene-5-carboxylic acid 
• 19432-69-0 methyl 5-methylthiophene-2-carboxylate 

Relevant academic research and scientific papers

COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Dihydro pyridine compound, its composition, preparation method and use

Disclosed dihydropyridine compounds are the compounds possessing the following general formula (I) as shown in the specification, wherein R1 is selected from hydrogen, halogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkylamino, substituted alkylamino, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic groups, substituted heterocyclic groups, ester group and amide group; R2 is selected from hydrogen, cyanogroup, alkyl, substituted alky, alkenyl, substituted alkenyl and acyl; or R2 and R3 form a fused ring; R3 is selected from alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; or R3 and R2 or R4 form a fused ring; R4 is selected from hydrogen, alkyl and substituted alkyl; or R4 and R3 or R5 form a fused ring; R5 is selected form alkyl, substituted alky, aryl, substituted aryl, heteroaryl and substituted heteroaryl; or R5 and R4 form a fused ring. The invention also discloses a preparation method of the compounds of the general formula (I), compositions containing the compounds of the general formula (I), and applications of the compositions to medicaments for treating cancers.

CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR

Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.

CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR

Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.

THIENOPYRAZOLES

Thienopyrazoles, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK).